![]() |
Ovarian Neoplasms |
Free Subscription
1 Am J Surg Pathol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Ovarian Neoplasms is free of charge.
Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in
Comparison With Their Corresponding Primary Tumors.
Am J Surg Pathol. 2024 Sep 13. doi: 10.1097/PAS.0000000000002308.
PubMed
Abstract available
Growth kinetics of high-grade serous ovarian cancer: implications for early
detection.
Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03082.
PubMed
Abstract available
Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.
Br J Cancer. 2025 Apr 23. doi: 10.1038/s41416-025-03012.
PubMed
Abstract available
The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and
Artificial Intelligence- Based Screening and Treatment.
Curr Treat Options Oncol. 2025 Jun 9. doi: 10.1007/s11864-025-01331.
PubMed
Abstract available
Disparities in hysterectomy-corrected endometrial cancer incidence trends by
histologic subtype among racial/ethnic groups in California, 2012-2019.
Gynecol Oncol. 2025;197:34-42.
PubMed
Abstract available
Molecular subgroup-specific prognostic value of semiquantitative lymphovascular
space invasion in early-stage endometrioid endometrial cancer.
Gynecol Oncol. 2025;197:96-101.
PubMed
Abstract available
Association of endometrial cancer epigenetic mismatch repair deficiency with
clinicopathologic factors and survival in a large, diverse community-based
cohort.
Gynecol Oncol. 2025;197:102-109.
PubMed
Abstract available
Impact of mismatch repair (MMR) status on recurrence in high intermediate risk
endometrial cancer.
Gynecol Oncol. 2025;197:116-120.
PubMed
Abstract available
Whole-exome sequencing provides assessment of homologous recombination deficiency
for identification of PARPi-responsive ovarian tumors.
Gynecol Oncol. 2025;197:139-145.
PubMed
Abstract available
Ovarian cancer risk and survival according to tumor sex hormone receptor
expression: An ovarian Cancer association consortium and ovarian tumor tissue
analysis consortium pooled analysis.
Gynecol Oncol. 2025;198:112-129.
PubMed
Abstract available
Use of statins and risk of ovarian cancer: evidence on effect modification by
parity, menopause and endometriosis from nationwide nested case-control studies.
Gynecol Oncol. 2025;198:130-136.
PubMed
Abstract available
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high
grade serous carcinoma is dependent on chemotherapy response score.
Hum Pathol. 2025;159:105800.
PubMed
Abstract available
The Spectrum of Vascular Lesions of the Upper Female Genital Tract: A Report of
55 Cases.
Int J Gynecol Pathol. 2025;44:291-307.
PubMed
Abstract available
Case Report: ESR1::CITED2 Fusion in a Malignant Uterine Tumor Resembling Ovarian
Sex Cord Tumor.
Int J Gynecol Pathol. 2025;44:368-373.
PubMed
Abstract available
Lamin A and Emerin Protein Expression Remains Consistently Low and Nuclear Size
is Unchanged in Normal Endometrium, Precancerous Lesions, and Endometrioid
Carcinoma.
Int J Gynecol Pathol. 2025;44:340-348.
PubMed
Abstract available
HER2 Status in Low-grade Serous Ovarian Tumors.
Int J Gynecol Pathol. 2025;44:331-335.
PubMed
Abstract available
Retraction Notice to: The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell
Proliferation and Metastasis by Targeting URI.
Mol Ther Oncol. 2025;33:200991.
PubMed
Abstract available
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of
tubo-ovarian high-grade serous carcinoma.
Proc Natl Acad Sci U S A. 2025;122:e2426909122.
PubMed
Abstract available
CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical
strategies.
Semin Oncol. 2025;52:152370.
PubMed
Abstract available
Thank you for your interest in scientific medicine.